Board of Directors
Dr. Bassil Dahiyat co-founded Xencor in 1997 to commercially leverage his and Dr. Stephen Mayo’s seminal work at Caltech on proteins and the development of Protein Design Automation™ technology. Under Dr. Dahiyat’s leadership, Xencor has applied PDA to develop a pipeline of proprietary protein and antibody drug candidates, both internally and in partnership with leading biotechnology and pharmaceutical companies. He drives the company’s fundraising efforts, and has secured more than $85 million in financing to date. Dr. Dahiyat also leads the company’s scientific programs and has been instrumental in growing the company’s broad intellectual property portfolio. He is an inventor on 60 patents and patent applications, including Xencor’s Protein Design Automation® platform, and a co-author of 18 scientific papers. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003′s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and Caltech. Dr. Dahiyat holds a Ph.D. in chemistry from Caltech and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University.
Dr. Carter was appointed Chairman of the Board of Xencor, Inc. in December 2009. In November 2009, he joined Immune Design Corp. where he serves as Executive Chairman of the Board. In addition to his duties at Immune Design, Dr. Carter serves as Chairman of the Board at the TB Alliance, and is a member of a number of other Boards, including Moksha8, QLT, Inc., and Dr. Reddy’s Lab. Prior to joining Immune Design, Dr. Carter was a member of the management team at ZymoGenetics, Inc. where he held various positions, including Chief Executive Officer from April 1998 to January 2009. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988 Novo Nordisk A/S acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
Robert F. Baltera, Jr. is a seasoned pharmaceutical industry executive and board member of several healthcare companies. Most recently, he was the CEO of Amira Pharmaceuticals, which was acquired by Bristol-Meyers Squibb Company for $325M upfront and $150M in future milestones. He was instrumental in focusing Amira's development efforts, strengthening its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Before becoming Amira’s CEO, Mr. Baltera worked for 17 years at Amgen, during which time he held a number of senior management positions, the last being vice president of corporate and contract manufacturing. Mr. Baltera served as the team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.
Mr. Baltera serves in senior roles in several organizations, including the Executive Chairman of the Board of Directors of Adheron Therapeutics, member Board of Directors Organovo Holdings (ONVO), member Board of Directors of Panmira Pharmaceuticals, member Board of Directors of San Diego Venture Group, and member the Board of Trustees of the Keck Graduate Institute. Mr. Baltera has an M.B.A. from the Anderson School at UCLA and earned his B.S. in microbiology and a M.S. in genetics from The Pennsylvania State University. In 2013 Mr. Baltera was awarded the Eberly College of Science (Pennylvania State University) Outstanding Alumni Award.
Jonathan J. Fleming is President and Treasurer of NEHI, a national health care policy think tank. Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, Massachusetts. Mr. Fleming has been in the investment business for more than 29 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. Mr. Fleming is a director of several private early stage life science companies. He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2003, and is an advisor to the SBIR program of the National Cancer Institute. Mr. Fleming holds a Master's degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs.
Between 1996 and 2001, Mr. Stafford was a Managing Director of Stafford Trading, Inc., a business primarily involved in proprietary trading operations and venture capital investments. The company, headquartered in Chicago, operated a successful specialist and market making business and conducted proprietary trading in equities, futures and fixed income products. Mr. Stafford’s venture capital activities consisted of investments in over 40 companies, and he is a Board Member on several of these companies, including Clinical Micro Sensors, Inc., Xencor and All Optical Networks, Inc. At the end of 2001, the Company was purchased by TD Options, LLC and Mr. Stafford became Chief Executive Officer of Ronin Capital, LLC, a registered broker dealer with proprietary trading operations encompassing equity, fixed income and derivative securities. The Company is a Member of The Chicago Board Options Exchange, The Chicago Board of Trade, The Chicago Mercantile Exchange and other U.S. principal exchanges. Mr. Stafford attended The University of Chicago.
Mr. Gustafson has more than 20 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations. Currently, Mr. Gustafson serves as executive vice president, chief financial officer and principal accounting officer at Spectrum Pharmaceuticals, Inc. Prior to that, he served as chief financial officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years most recently as vice president, finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as CFO of Amgen International and resided in Zug, Switzerland. Mr. Gustafson holds a Bachelors of Arts degree in accounting from North Park University in Chicago and a Masters in business administration from University of California, Los Angeles.